ZIKV Strains Elicit Different Inflammatory and Anti-Viral Responses in Microglia Cells

Viruses. 2023 May 26;15(6):1250. doi: 10.3390/v15061250.

Abstract

In recent years, the Zika Virus (ZIKV) has caused pandemic outbreaks associated with a high rate of congenital ZIKV syndrome (CZS). Although all strains associated with worldwide outbreaks derive from the Asian lineage, the reasons for their enhanced spread and severity are not fully understood. In this study, we conducted a comparative analysis of miRNAs (miRNA-155/146a/124) and their cellular targets (SOCS1/3, SHP1, TRAF6, IRAK1), as well as pro- and anti-inflammatory and anti-viral cytokines (IL-6, TNF-α, IFN-γ, IL-10, and IFN-β) and peroxisome proliferator-activated receptor γ (PPAR-γ) expression in BV2 microglia cells infected with ZIKV strains derived from African and Asian lineages (ZIKVMR766 and ZIKVPE243). BV2 cells were susceptible to both ZIKV strains, and showed discrete levels of viral replication, with delayed release of viral particles without inducing significant cytopathogenic effects. However, the ZIKVMR766 strain showed higher infectivity and replicative capacity, inducing a higher expression of microglial activation markers than the ZIKVPE243 strain. Moreover, infection with the ZIKVMR766 strain promoted both a higher inflammatory response and a lower expression of anti-viral factors compared to the ZIKVPE243 strain. Remarkably, the ZIKKPE243 strain induced significantly higher levels of the anti-inflammatory nuclear receptor-PPAR-γ. These findings improve our understanding of ZIKV-mediated modulation of inflammatory and anti-viral innate immune responses and open a new avenue to explore underlining mechanisms involved in the pathogenesis of ZIKV-associated diseases.

Keywords: PPAR-γ; Zika virus; inflammatory response; miRNA; microglia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • Humans
  • MicroRNAs*
  • Microglia / metabolism
  • Peroxisome Proliferator-Activated Receptors
  • Virus Replication / physiology
  • Zika Virus Infection*
  • Zika Virus* / physiology

Substances

  • Peroxisome Proliferator-Activated Receptors
  • Antiviral Agents
  • MIRN155 microRNA, human
  • MicroRNAs

Grants and funding

This research was funded by: Fundação de Apoio à Pesquisa do Distrito Federal (FAP-DF), grant number 193001532/2016 and 0193.001646/2017 to BMR, ERA, and GAA; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, LBA: 310867/2018-5); Coordenação de Aperfeiçoamento Pessoal de Nível Superior (CAPES); Rede Corona-ômica BR MCTI/FINEP affiliated to RedeVírus/MCTI (FINEP = 01.20.0029.000462/20), CNPq 404096/2020-4); Carlos Chagas Filho Research Support Foundation (FAPERJ; LBA E-26/201.206/2021, E-26/210.371/2019); and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ, SVAC: 200.302/2020, LBA: 201.324/2016). L.B.A and L.M.M are recipients of a CNPq fellowship; SVAC is a recipient of a FAPERJ fellowship.